Filed in archive
Corporate and Industrial News
, Drugs, Vaccines and Therapeutics
, Patents and Intellectual Property Rights
by ruth on February 14, 2006

Biovitrum's lead compound, 11beta-HSD1 enzyme inhibitors, are currently under early clinical development.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/15480
Mr Wong
Vote for Amgen Gains Worldwide Rights to Biovitrum's Lead Candidate For Type 2 Diabetes:
|
Rating: 6.00 out of 1 vote(s) cast.
|
Response from:
James Hatton
(02/16/06 3:26pm)
Subscribe
Use the search to look for other interesting posts
| RSS | See all blog subscribe options |
|
What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |








When they signed the 2003 license (the winner of the "Best of Biotech 2004" award for "Most Creative and Significant Deal"), the September 8, 2003 press release disclosed that the license fee was $87 million.